18683235. Targeting Oncogenic KRAS with Molecular Brush-Conjugated Antisense Oligonucleotide (Northeastern University)
Targeting Oncogenic KRAS with Molecular Brush-Conjugated Antisense Oligonucleotide
Organization Name
Inventor(s)
Targeting Oncogenic KRAS with Molecular Brush-Conjugated Antisense Oligonucleotide
This abstract first appeared for US patent application 18683235 titled 'Targeting Oncogenic KRAS with Molecular Brush-Conjugated Antisense Oligonucleotide
Original Abstract Submitted
Provided herein are, in various embodiments, methods and compositions comprising polyethylene glycol (PEG)-conjugated oligonucleotides (e.g., anti-sense oligonucleotides) for treatment of cancer. In certain embodiments, the disclosure provides for methods and compositions for enhancing efficacy of anti-sense oligonucleotides. In still further embodiments, the disclosure provides methods and compositions for treatment of non-small cell lung cancer.